Evidence map›Paper›PMID 26881390›Full record

SynthesisOncotarget2016

A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.

Jacek Marzec, Xueying Mao, Meiling Li, Meilin Wang, Ninghan Feng, Xin Gou, Guomin Wang, Zan Sun, Jianfeng Xu, Hua Xu and 36 more

Open access · diamondAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  9. Review
  10. Article
  11. Association betweenMolecular & cellular oncology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 14 institutions in 3 countries.

Jacek MarzecCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Xueying MaoCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Meiling LiDepartment of Epidemiology, Second Military Medical University, Shanghai, 200433, China.
Meilin WangDepartment of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, 210029, China.
Ninghan FengDepartment of Urology, Wuxi Second People's Hospital, Nanjing Medical University, Wuxi, 214002, China.
Xin GouDepartment of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.
Guomin WangDepartment of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, 200032, China.
Zan SunLiaoning People's Hospital and Center of Experiment and Technology, China Medical University, Shenyang, 110001, China.
Jianfeng XuProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL 60201, U.S.A.
Hua XuDepartment of Urology, Tongji Hospital, Huazhong Science and Technology University, Wuhan, 430030, China.
Xiaoping ZhangDepartment of Urology, Xiehe Hospital, Huazhong Science and Technology University, Wuhan, 430022, China.
Shan-Chao ZhaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Guoping RenDepartment of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, 310009, China.
Yongwei YuDepartment of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China.
Yudong WuDepartment of Urology, First Affiliated Hospital, Medical College, Zhengzhou University, Zhengzhou, 450003, China.
Ji WuDepartment of Urology, North Sichuan Medical College, Nanchong, 637000, China.
Yao XueDepartment of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, 210029, China.
Bo ZhouDepartment of Nutrition Science, Shenyang Medical College, Shenyang, 110034, China.
Yanling ZhangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, 310009, China.
Xingxing XuDepartment of Epidemiology, Second Military Medical University, Shanghai, 200433, China.
Jie LiDepartment of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.
Weiyang HeDepartment of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.
Sara BenllochCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge-Strangeways Research Laboratory, Cambridge, CB1 8RN, UK.
Helen Ross-AdamsCancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Li ChenDepartment of Urology, Xiehe Hospital, Huazhong Science and Technology University, Wuhan, 430022, China.
Jucong LiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yingqia HongDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zsofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Xingang CuiDepartment of Urology, Changzheng Hospital, The Second Military Medical University, Shanghai, 200003, China.
Jianguo HouDepartment of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, 200032, China.
Lei XuDepartment of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, 200032, China.
Changjun YinDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Yuanping ZhouDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
David E NealCancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Tim OliverCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Guangwen CaoDepartment of Epidemiology, Second Military Medical University, Shanghai, 200433, China.
Zhengdong ZhangDepartment of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, 210029, China.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge-Strangeways Research Laboratory, Cambridge, CB1 8RN, UK.
Claude ChelalaCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
PRACTICAL Consortium
CHIPGECS Group
Ali Amin Al OlamaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge-Strangeways Research Laboratory, Cambridge, CB1 8RN, UK.
Rosalind A EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Hongwei ZhangDepartment of Epidemiology, Second Military Medical University, Shanghai, 200433, China.
Yong-Jie LuCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Queen Mary University of London · GBSecond Military Medical University · CNNanfang Hospital · CNFudan University · CNUniversity of Cambridge · GBCancer Research UK · GBInstitute of Cancer Research · GBNorthShore University HealthSystem · USNorth Sichuan Medical University · CNRoyal Marsden NHS Foundation Trust · GBShenyang Medical College · CNJiangsu Province Hospital · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNTongji Hospital · CN

Funding

Cancer Research UK 10118Cancer Research UK 15007Cancer Research UK 16563Cancer Research UK 17528
6 · The paper itself

Abstract

Prostate cancer predisposition has been extensively investigated in European populations, but there have been few studies of other ethnic groups. To investigate prostate cancer susceptibility in the under-investigated Chinese population, we performed single-nucleotide polymorphism (SNP) array analysis on a cohort of Chinese cases and controls and then meta-analysis with data from the existing Chinese prostate cancer genome-wide association study (GWAS). Genotyping 211,155 SNPs in 495 cases and 640 controls of Chinese ancestry identified several new suggestive Chinese prostate cancer predisposition loci. However, none of them reached genome-wide significance level either by meta-analysis or replication study. The meta-analysis with the Chinese GWAS data revealed that four 8q24 loci are the main contributors to Chinese prostate cancer risk and the risk alleles from three of them exist at much higher frequencies in Chinese than European populations. We also found that several predisposition loci reported in Western populations have different effect on Chinese men. Therefore, this first extensive single-nucleotide polymorphism study of Chinese prostate cancer in comparison with European population indicates that four loci on 8q24 contribute to a great risk of prostate cancer in a considerable large proportion of Chinese men. Based on those four loci, the top 10% of the population have six- or two-fold prostate cancer risk compared with men of the bottom 10% or median risk respectively, which may facilitate the design of prostate cancer genetic risk screening and prevention in Chinese men. These findings also provide additional insights into the etiology and pathogenesis of prostate cancer.

Indexed as

Genome-Wide Association StudyPolymorphism, Single NucleotideAsian PeopleChinaChromosomes, Human, Pair 8Gene FrequencyGenetic LociGenetic Predisposition to DiseaseGenotypeHumansMaleProstatic NeoplasmsRisk FactorsWhite PeopleChinese prostate cancergenetic riskpopulation differencepredispositionsingle-nucleotide polymorphism

Identifiers

PMID26881390
PMCPMC5008293
OpenAlexW2271391387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.